Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLK286 + Docetaxel in Platinum-Resistant NSCLC
NCT00047801Phase 2Completed
- Sponsor
- Telik, Inc.
- Start
- Oct 2002
- Primary completion
- Sep 2004
- Modality
- DNA Intercalators/Alkylators, Peptides, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of canfosfamide in non-small cell lung cancer (NSCLC), sponsored by Telik, Inc.. Started Oct 2002; status: completed.
02
Drugs
canfosfamide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00047801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00047801.